يعرض 1 - 10 نتائج من 32 نتيجة بحث عن '"Borges, Silvana"', وقت الاستعلام: 1.08s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية
  6. 6

    المصدر: Research, Society and Development; Vol. 10 No. 5; e31710514892
    Research, Society and Development; Vol. 10 Núm. 5; e31710514892
    Research, Society and Development; v. 10 n. 5; e31710514892
    Research, Society and Development
    Universidade Federal de Itajubá (UNIFEI)
    instacron:UNIFEI

    وصف الملف: application/pdf

  7. 7
    دورية أكاديمية
  8. 8
  9. 9
    كتاب

    المؤلفون: Borges, Silvana de Oliveira

    المساهمون: Roballo, Carlos Alberto Moreira, 1968-, Universidade Federal do Paraná. Setor de Educação. Curso de Especializaçao em Educação a Distância

    مصطلحات موضوعية: Ensino à distância - Paraná, Ensino superior

    وصف الملف: 1 arquivo (45 p.).; application/pdf

  10. 10
    دورية أكاديمية

    المساهمون: Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, Division of Biostatistics, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, Department of Oncology, Johns Hopkins University, Baltimore, Maryland, Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana

    وصف الملف: application/pdf

    العلاقة: Borges, Silvana; Desta, Zeruesenay; Jin, Yan; Faouzi, Azzouz; Robarge, Jason D.; Philip, Santosh; Nguyen, Anne; Stearns, Vered; Hayes, Daniel; Rae, James M.; Skaar, Todd C.; Flockhart, David A.; Li, Lang (2010). "Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients." The Journal of Clinical Pharmacology 50(4).; https://hdl.handle.net/2027.42/97292Test; The Journal of Clinical Pharmacology; Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004; 351: 2827 – 2831.; Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004; 310: 1062 – 1075.; Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics. 1997; 7: 375 – 379.; Dahl ML, Johansson I, Palmertz MP, Ingelman‐Sundberg M, Sjoqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther. 1992; 51: 12 – 17.; Hou ZY, Pickle LW, Meyer PS, Woosley RL. Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther. 1991; 49: 410 – 419.; Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997; 60: 284 – 295.; Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004; 369: 23 – 37.; Ingelman‐Sundberg M, Daly AK, Nebert DW. Human Cytochrome P450 (CYP) Allele Nomenclature Committee Web site. www.imm.ki.seCYPalleles. Accessed December 24, 2009.; Dahl ML, Johansson I, Bertilsson L, Ingelman‐Sundberg M, Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population: analysis of the molecular genetic basis. J Pharmacol Exp Ther. 1995; 274: 516 – 520.; Lundqvist E, Johansson I, Ingelman‐Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene. 1999; 226: 327 – 338.; Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007; 46: 242 – 251.; Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants—a pilot study. Clin Pharmacol Ther. 2004; 75: 386 – 393.; Schillevoort I, de Boer, A, van der Weide, J, et al. Antipsychotic‐induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case‐control study. Pharmacogenetics. 2002; 12: 235 – 240.; Shams ME, Arneth B, Hiemke C, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006; 31: 493 – 502.; Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther. 2007; 81: 429 – 444.; Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol‐associated adverse effects. Clin Pharmacol Ther. 2002; 72: 429 – 437.; Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007; 101: 113 – 121.; Kawanishi C, Furuno T, Kishida I, Matsumura T, Kosaka K. A patient with treatment‐resistant schizophrenia and cytochrome P4502D6 gene duplication. Clin Genet. 2002; 61: 152 – 154.; Kawanishi C, Lundgren S, Agren H, Bertilsson L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse: a pilot study. Eur J Clin Pharmacol. 2004; 59: 803 – 807.; Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004; 9: 442 – 473.; Dalen P, Frengell C, Dahl ML, Sjoqvist F. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit. 1997; 19: 543 – 544.; de Leon J, Dinsmore L, Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol. 2003; 23: 420 – 421.; Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra‐rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007; 7: 257 – 265.; Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine‐prescribed mother. Lancet. 2006; 368: 704.; Chou WH, Yan FX, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol. 2000; 20: 246 – 251.; Flockhart DA. Cytochrome P450 drug interactions. http:medicine.iupui.educlinpharmddis. Access December 24, 2009.; Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005; 97: 30 – 39.; Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006; 80: 61 – 74.; Cai WM, Nikoloff DM, Pan RM, et al. CYP2D6 genetic variation in healthy adults and psychiatric African‐American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J. 2006; 6: 343 – 350.; Li L, Pan RM, Porter TD, et al. New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes. Drug Metab Dispos. 2006; 34, 1411 – 1416.; Zineh I, Beitelshees AL, Gaedigk A, et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol. Ther. 2004; 76: 536 – 544.; Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008; 83: 234 – 242.; Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003; 95: 1758 – 1764.; Food and Drug Administration. Guidance for industry drug interaction studies—study design, data analysis, and implications for dosing and labeling (Draft Guidance). September 2006. http:www.fda.govdownloadsDrugsGuidanceComplianceRegulatoryInformationGuidancesucm072101.pdf. Accessed December 24, 2009.; Laine K, Tybring G, Hartter S, et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001; 70: 327 – 335.; Ingelman‐Sundberg M, Johansson I, Persson I, et al. Genetic polymorphism of cytochrome P450: functional consequences and possible relationship to disease and alcohol toxicity. EXS. 1994; 71: 197 – 207.; Ingelman‐Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004; 25: 193 – 200.